

Date Mailed:

Form 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	Docket Number: 184.4USWO		Int'l Appl. No. 10/527271 PCT/GB03/003951
	Applicant: Alan Crossman et al.		U.S. Serial No.: To be Assigned
	Filing Date: Herewith	Group Art Unit: N/A	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	4,322,346	03/30/82	Korosi et al.				
	6,200,970	03/13/01	Ling et al.				

FOREIGN PATENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	EP0900568	03/10/99	Europe				
	WO02088096	11/07/02	PCT				
	WO02094189	11/28/02	PCT				

NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Beers M. and Berkow R., "The Merck Manual of Diagnosis and Therpay, 17 th Edition", 1999, Merck Research Laboratories Whitehouse Station, N.J., pp. 1462-1473, XP002267011.
		Beloborodova et al., "Method of Treatment of Hypertension-Hyperkinetic form of Dyskinesia of Biferous Ways in Young Persons", 12/27/02, Abstract, XP002266976.
		Brotchie J.M. et al., "The Effects of Tofisopam on the Actions Induced by L-DOPA Administration in the MPTP - Lesioned Non-Human Primate Model of Parkinson's Disease", Society for Neuroscience Abstract Viewer and Itinerary Planner, Vol. 2002, 2002, page Abstract No. 165.18, XP008026196.
		Konitsiotis S. et al., "AMPA Receptor Blockade Improves Levodopa-Induced Dyskinesia in MPTO Monkeys", Neurology, Vol. 54, No. 8, April 25, 2000, pp. 1589-1595, XP008026187.
		Revutsky E. L. et al., "Prophylaxis of Meteopathological Reactions in Patients with Ischemic heart Disease and Neurocirculatory Dystonia", Vrachebnoe Delo 1988 Russia, No. 2, 1988, pp. 7-10, XP008026189.
		Solyom S. et al., "Non-Competitive AMPA Antagonists of 2,3-Benzodiazepin Type", Current Pharmaceutical Design 2002, Netherlands, Vol. 8, No. 10, 2002, pp. 913-939, XP008026188.
		Tarnawa I. et al., "2,3-Benzodiazepine AMPA Antagonists", Restorative Neurology and Neuroscience, 1998, Vol. 13, pp. 41-57, XP008026184.

EXAMINER: /Sahar Javanmard/	DATE CONSIDERED: 07/16/2008
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

G&C 184.4-US-WO

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./